Department of Radiation Therapy, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse- Oncopole, Toulouse, France.
Department of Radiation Therapy, Institut Curie, Paris, France; Institut Curie - Centre de Protontherapie d', Orsay, Orsay, France.
Radiother Oncol. 2024 May;194:110157. doi: 10.1016/j.radonc.2024.110157. Epub 2024 Feb 16.
Ependymoma is the third most frequent childhood braintumor. Standard treatment is surgery followed by radiation therapy including proton therapy (PBT). Retrospective studies have reported higher rates of brainstem injury after PBT than after photon therapy (XRT). We report a national multicenter study of the incidence of brainstem injury after XRT versus PBT, and their correlations with dosimetric data.
We included all patients aged < 25 years who were treated with PBT or XRT for intracranial ependymoma at five French pediatric oncology reference centers between 2007 and 2020. We reviewed pre-irradiation MRI, follow-up MRIs over the 12 months post-treatment and clinical data.
Of the 83 patients, 42 were treated with PBT, 37 with XRT, and 4 with both (median dose: 59.4 Gy, range: 53‑60). No new or progressive symptomatic brainstem injury was found. Four patients presented asymptomatic radiographic changes (punctiform brainstem enhancement and FLAIR hypersignal), with median onset at 3.5 months (range: 3.0‑9.4) after radiation therapy, and median offset at 7.6 months (range: 3.7‑7.9). Two had been treated with PBT, one with XRT, and one with mixed XRT-PBT. Prescribed doses were 59.4, 55.8, 59.4 and 54 Gy.
Asymptomatic radiographic changes occurred in 4.8% of patients with ependymoma in a large national series. There was no correlation with dose or technique. No symptomatic brainstem injury was identified.
室管膜瘤是儿童第三常见脑肿瘤。标准治疗是手术,随后是放疗,包括质子治疗(PBT)。回顾性研究报告称,PBT 后脑干损伤的发生率高于光子治疗(XRT)。我们报告了一项全国多中心研究,比较了 XRT 与 PBT 治疗后脑干损伤的发生率及其与剂量学数据的相关性。
我们纳入了 2007 年至 2020 年间在法国五家儿科肿瘤学参考中心接受 PBT 或 XRT 治疗颅内室管膜瘤的所有<25 岁患者。我们回顾了放疗前 MRI、治疗后 12 个月的随访 MRI 和临床数据。
83 例患者中,42 例接受 PBT 治疗,37 例接受 XRT 治疗,4 例同时接受两种治疗(中位剂量:59.4Gy,范围:53-60)。未发现新的或进展性症状性脑干损伤。4 例患者出现无症状性影像学改变(点状脑干强化和 FLAIR 高信号),中位发病时间为放疗后 3.5 个月(范围:3.0-9.4),中位消退时间为 7.6 个月(范围:3.7-7.9)。其中 2 例接受 PBT 治疗,1 例接受 XRT 治疗,1 例接受混合 XRT-PBT 治疗。处方剂量分别为 59.4、55.8、59.4 和 54Gy。
在一项大型全国性系列研究中,4.8%的室管膜瘤患者出现无症状性影像学改变。与剂量或技术无相关性。未发现症状性脑干损伤。